Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
Because monotherapy with 19-nortestosterone hexyloxyphenylpropionate (Anadur, Pharmacia Arzneimittel, Ratingen, Federal Republic of Germany) suggested improved results for male contraception compared with available testosterone esters, it was tested for induction of complete azoospermia when combined with depot-medroxyprogesterone acetate (DMPA, Clinovir, Upjohn GmbH, Heppenheim, Federal Republic of Germany). Twelve men were treated for 7 weeks with weekly intramuscular (IM) injections of 200 mg Anadur followed by 3-weekly IM injections of Anadur up to week 15. Clinovir (250 mg) IM was administered at the start of treatment and during weeks 6 and 12. Anadur and Clinovir suppressed serum gonadotropins. Although serum testosterone declined steeply, in general, libido and potency were not impaired. Sperm concentrations were reduced significantly after 3 weeks of treatment. Lowest sperm counts were seen during week 8 of follow-up, when only 2 volunteers showed measurable sperm counts of 2.1 and 3.0 X 10(6)/ml, with a declining tendency. After 43 weeks, sperm concentrations were still below pretreatment range in 2 men, but later returned to pretreatment values. Computerized sperm motion analysis revealed that motility parameters in the residual sperm were reduced. In vitro analysis excluded a direct effect of medroxyprogesterone acetate in seminal plasma on sperm motion. The data indicate that the combination of Anadur with Clinovir increases the rate of azoospermia in normal volunteers seen under Anadur monotherapy, although the goal of azoospermia in all participants was not quite achieved.
Knuth
U A
UA
Max Planck Clinical Research Unit for Reproductive Medicine, University, Münster, Federal Republic of Germany.
Yeung
C H
CH
Nieschlag
E
E
D045930:Anabolic Agents; D003272:Contraceptive Agents, Male; D004347:Drug Interactions; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D066298:In Vitro Techniques; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D009277:Nandrolone / Q000031:analogs & derivatives* / Q000097:blood; D012661:Semen / Q000032:analysis; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects
D045930:Anabolic Agents; D003272:Contraceptive Agents, Male; C034345:19-nortestosterone 4-hexoxyphenylpropionate; D009277:Nandrolone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone